Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00111540
First received: May 23, 2005
Last updated: September 18, 2013
Last verified: September 2013
  Purpose

This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: exenatide
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Change in HbA1c (glycosylated hemoglobin) from Visit 1 to each protocol visit [ Time Frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target) ] [ Designated as safety issue: No ]
    Change in HbA1c from Visit 1 to each visit up to open-ended study termination

  • Change in body weight from Visit 1 to each protocol visit [ Time Frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target) ] [ Designated as safety issue: No ]
    Change in body weight (kg) from Visit 1 to each visit up to open-ended study termination

  • Change in fasting plasma glucose from Visit 1 to each protocol visit [ Time Frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target) ] [ Designated as safety issue: No ]
    Change in fasting plasma glucose from Visit 1 to each visit up to open-ended study termination

  • Change in lipids from Visit 1 to each protocol visit [ Time Frame: Day 1, Weeks 2, 4, 8, 15, 22, 30, 38, 46 and every 12 weeks while on study (78 week target) ] [ Designated as safety issue: No ]
    Change in lipids from Visit 1 to each visit up to open-ended study termination


Enrollment: 456
Study Start Date: November 2002
Study Completion Date: September 2006
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Exenatide
Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
Drug: exenatide
subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
Other Names:
  • Byetta
  • exendin-4
  • AC2993

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject has an HbA1c value <=11.0%
  • The subject has a body mass index (BMI) of 25 kg/m^2 to 45 kg/m^2, inclusive

Exclusion Criteria:

  • Is currently treated with certain medications, including exogenous insulin
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00111540

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, California
Research Site
Anaheim, California, United States
Research Site
Bellflower, California, United States
Research Site
Burlingame, California, United States
Research Site
Chula Vista, California, United States
Research Site
Concord, California, United States
Research Site
Encino, California, United States
Research Site
Fremont, California, United States
Research Site
La Jolla, California, United States
Research Site
Los Gatos, California, United States
Research Site
Moreno Valley, California, United States
Research Site
Redwood City, California, United States
Research Site
San Mateo, California, United States
Research Site
Walnut Creek, California, United States
United States, Colorado
Research Site
Aurora, Colorado, United States
Research Site
Denver, Colorado, United States
United States, Florida
Research Site
Gainesville, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Largo, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Ocala, Florida, United States
United States, Georgia
Research Site
Blairsville, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
United States, Kentucky
Research Site
Lexington, Kentucky, United States
United States, Louisiana
Research Site
Covington, Louisiana, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Slidell, Louisiana, United States
United States, Michigan
Research Site
Detroit, Michigan, United States
United States, Minnesota
Research Site
Edina, Minnesota, United States
Research Site
Minneapolis, Minnesota, United States
United States, Mississippi
Research Site
Gulfport, Mississippi, United States
Research Site
Picayune, Mississippi, United States
United States, Missouri
Research Site
Chesterfield, Missouri, United States
Research Site
St. Louis, Missouri, United States
United States, Montana
Research Site
Butte, Montana, United States
United States, Nevada
Research Site
Las Vegas, Nevada, United States
United States, New York
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
United States, North Carolina
Research Site
Cary, North Carolina, United States
Research Site
Durham, North Carolina, United States
United States, Ohio
Research Site
Columbus, Ohio, United States
Research Site
Marion, Ohio, United States
Research Site
Maumee, Ohio, United States
Research Site
Mentor, Ohio, United States
United States, Oklahoma
Research Site
Clinton, Oklahoma, United States
Research Site
Oklahoma City, Oklahoma, United States
United States, Oregon
Research Site
Medford, Oregon, United States
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Camp Hill, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
United States, Texas
Research Site
Dallas, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Midland, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Utah
Research Site
Salt Lake City, Utah, United States
United States, Washington
Research Site
Olympia, Washington, United States
Research Site
Spokane, Washington, United States
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.
  More Information

No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00111540     History of Changes
Other Study ID Numbers: 2993-119
Study First Received: May 23, 2005
Last Updated: September 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
exenatide
diabetes
Amylin
exendin-4

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Exenatide
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014